https://www.ocrevus.com

Contact Information:

James Eggen
Cell:  480-823-2966
eggen.james@gene.com

Joy Bietz
Cell: 520-345-2526
beitzj@gene.com

Jeff Carlson
MS/NMO Therapeutic Area Manager - Minnesota/North Dakota
Cell: 612-968-0378
jeffreca@gene.com

Google Meets Link
Live interaction hours available during pre-conference hours and breaks as noted on the course agenda.

Virtual Exhibit Hall Home

For more than 40 years, we’ve been following the science,
seeking solutions to unmet medical needs. As a proud member of the Roche Group,
we make medicines to treat patients with serious medical conditions.

About OCREVUS

OCREVUS® (ocrelizumab) is a therapeutic monoclonal antibody that represents a different scientific approach to treating MS. It targets a type of immune cell called a CD20-positive B cell that plays a key role in the disease. OCREVUS is approved by the FDA to treat relapsing or primary progressive forms of multiple sclerosis (MS). OCREVUS is given once every six months by an intravenous (IV) infusion.1

FIRST AND ONLY approved disease-modifying therapy for primary progressive multiple sclerosis (PPMS), a highly disabling form of MS1,2
FIRST AND ONLY medicine approved to treat two types of MS: relapsing forms of MS (RMS) and PPMS1

Ocrevus Open Label Extension

Ocrevus Patient Experience 5 year

Enspryng